Supplementary Tables 1-3, Figures 1-6 from Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non–Small Cell Lung Cancer Patients (SAKK 19/05 trial)

Supplementary Tables 1-3, Figures 1-6. Supplementary Table 1: Statistical analysis of differences between the study group and the remaining group of patients for several variables. Supplementary Table 2: Primers used for the RT-qPCR assays. Supplementary Table 3: Leave-one-out cross-validation of the angiogenesis-associated and hypoxia gene signatures. Supplementary Figure 1: Average gene expression levels for the top 10-ranked angiogenesis signature calculated based on the microarray data (N = 42 patients) for low (Cluster A1), high (Cluster A2) and medium (Cluster A3) risk patients. Supplementary Figure 2: Average gene expression levels for the top 10-ranked hypoxia response signature calculated based on the microarray data (N = 42 patients). Supplementary Figure 3: Hierarchical clustering of top 10-ranked hypoxia-response genes significantly associated with TS, showing gene expression variation among patients. The heat map represents relative intensity values of gene expression levels. Supplementary Figure 4: Hierarchical clustering of top 10-ranked hypoxia-response genes significantly associated with OS, showing gene expression variation among patients. The heat map represents relative intensity values of gene expression levels. Supplementary Figure 5: Optimized between-group classification (OBC) sensitivity analysis for angiogenesis-associated signature (A) and hypoxia-response signature predictive of TTP under BE. Supplementary Figure 6: Association between the expression of 10-gene hypoxia-response signature predictive of TTP under BE in our study, and PFS of second line sorafenib-treated patients enrolled in the BATTLE-1 trial,1 GEO accession number: GSE33072;2 P = 0.0186, calculated by log-tank test.